AnGes, Inc. Announces Completion of Enrollment in its Phase Ib Clinical Trial of NF-B Decoy Oligo DNA for Chronic Discogenic Lumbar Back Pain in the United States
February 27, 2020 at 06:30 pm EST
Share
AnGes, Inc. announced the completion of enrollment in their Phase Ib clinical trial of NF-B decoy oligo DNA (hereinafter referred to as NF-B decoy) for Chronic Discogenic Lumbar Back Pain in the United States. The 25 subjects enrolled will be observed in a double blind manner to evaluate safety and efficacy for 6 months, followed by an unblinded Extension Period of another 6 months to assess longer term safety, tolerability and efficacy. Overview of Phase 1b clinical trial of NF-B decoy oligo DNA in the United States: Study Synopsis: Multicenter, double-blind, randomized, placebo-controlled, single ascending-dose, clinical study evaluating the safety, tolerability and exploratory efficacy of a single injection of intradiscal NF-B decoy in the subjects with chronic discogenic lumber back pain Number of subjects enrolled: 25 subjects; Observation period: 6 months of double-blinded assessment, followed by an additional 6-month extension study. Top-line results are expected to be released in fourth quarter of 2020.
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
AnGes, Inc. Announces Completion of Enrollment in its Phase Ib Clinical Trial of NF-B Decoy Oligo DNA for Chronic Discogenic Lumbar Back Pain in the United States
ANGES, INC. 
